MoonLake Immunotherapeutics (MLTX) Corporate Presentation summary

Company overview and strategy

• Founded in 2021, leveraging Nanobody® technology for inflammation, targeting a $40bn+ market.

• Public on Nasdaq since 2022, raising ~$750m to date.

• Focused on late-stage clinical development in dermatology and rheumatology, with a pipeline-in-a-product approach.

• Strategic imperatives include building the HS market, advancing PsA, unlocking new indications, and executing with excellence.

• Financially stable with cash runway expected through at least end of 2026.

Technology and product differentiation

• Sonelokimab (SLK) is a tri-specific Nanobody® targeting IL-17A, IL-17F, and albumin, offering smaller size and multi-domain binding compared to traditional antibodies.

• SLK uniquely binds all IL-17 dimers with similar affinity, differentiating it from other IL-17-targeting therapies.

• Nanobody® design enables subcutaneous, monthly dosing with rapid onset and durable response.

• Demonstrates leading efficacy in deep dermal lesions and inflammatory remission in HS.

• Biomarker data show normalization of disease activity markers by week 12.

Clinical development and results

• Successfully completed Phase 2b trials in HS (MIRA), PsA (ARGO), and psoriasis, with Phase 3 trials initiated in 2024.

• HS: SLK achieved highest ever HiSCR75 response, rapid and extensive resolution of deep dermal lesions, and significant pain reduction.

• PsA: SLK met primary and key secondary endpoints, showing superior multidomain responses and potential in TNF non-responders.

• New indications in palmoplantar pustulosis (PPP), adolescent HS, and axSpA are in Phase 2/3 development.

• Phase 3 programs (VELA for HS, IZAR for PsA) are progressing on schedule, with major data readouts expected in 2025-2026.